OncoSenX is a late preclinical-stage oncology company developing therapeutics designed to kill cancer cells based on their genetics. Its core platform pairs a proprietary lipid nanoparticle (LNP) for cellular delivery with a selective, non-integrating DNA payload and an engineered promoter that drives expression of an inducible death protein only in target cells. The LNP is designed to deliver the DNA payload to solid tumors, and the platform can be programmed to implement logic gates (IF/OR/AND) to provide selectivity based on transcriptional activity. Company leadership frames the approach as a non-viral gene therapy that could reduce toxicity and improve tolerability versus conventional chemotherapy and offer more precise targeting than biologics or CAR-T, if substantiated in the clinic. OncoSenX says the proceeds will accelerate preclinical research toward phase 1 clinical development; the team is preparing regulatory interactions and plans pivotal toxicology studies in anticipation of filing to begin human trials. The company is headquartered in Seattle, Washington, and is advancing its pipeline toward clinical entry.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2019